Mr. Erwin has overseen clinical operations for the nonprofit research organization since 2017, most recently serving as Executive Director.
SAN CARLOS, Calif. (March 4, 2025) — The Addario Lung Cancer Medical Institute (ALCMI) today announced the appointment of Richard Erwin to the ALCMI Board of Directors, effective February 25, 2025. Erwin was also named as the research organization's Chief Operating Officer. In his new role, he will lead the nonprofit group’s global growth strategy, business development, clinical trial operations, new medical site recruitment, and marketing.
“Richard brings decades of experience in clinical trials, research planning, and execution,” said ALCMI Chairman and CEO Dr. Ken Krantz. “His track record of building successful clinical operations and development partnerships is unmatched. He has a proven ability to scale operations and lead growth-stage clinical operation build-outs, and is well-known throughout the lung cancer research community. This, combined with his deep industry knowledge, makes him uniquely qualified to join our board and help lead this organization into the future.”
Erwin joined ALCMI in 2017 as Senior Director of Clinical Operations and was later named Executive Director. With his vision and leadership acumen, he is responsible for the organization’s impressive growth over the past eight years, which has led to over a dozen clinical trials and three published studies in major oncology journals. He has also positioned ALCMI as a trusted research trial partner, working alongside many of the world’s leading oncology research institutions, pharmaceutical industry representatives, and patient-led advocacy groups.
Richard brings with him over 30 years of global clinical development operations experience. He has served in leadership roles across the pharmaceutical, biotech, and medical nonprofit industries at notable bellwether companies like Amgen, British Biotech, Eli Lilly & Co., IQVIA, Neurocrine Biosciences, Otsuka, PaxVax, and others.
“ALCMI is well positioned for significant growth in the coming years, and I’m honored to join the board and help this organization take its place among the leading research institutions in lung cancer,” said Erwin. “In the next evolution of this organization, we’ll focus on investigator-initiated clinical trials to make advancements in early detection, mechanisms of treatment resistance, hereditary biomarkers for lung cancer, and risk factors in younger people. We’re also excited to move into correlative research at the intersection of lung cancers and other metabolic disorders, such as Lambert-Eaton Myasthenic Syndrome (LEMS) and Mesothelioma.”
Learn more about ALCMI’s current research projects at https://alcmi.org.
About ALCMI
The Addario Lung Cancer Medical Institute (ALCMI) is a nonprofit international consortium comprised of 25 of the world’s premier oncology research institutions. We partner with the top minds from the most respected medical facilities, providing financial support and access to a team of experts and staff to assist in launching and managing investigator-initiated clinical trials. We bridge the gap between clinical research organizations (CROs) and site management organizations (SMOs), resulting in a streamlined, agile process for quickly funding and initiating lung cancer research projects. We also focus on the patient’s journey through this disease with support and educational outreach. For more information, visit alcmi.org.
###
For more information, contact:
Wayne Niemi
